SG11201507390SA - Treatment of insulin resistance associated with prolonged physical inactivity - Google Patents

Treatment of insulin resistance associated with prolonged physical inactivity

Info

Publication number
SG11201507390SA
SG11201507390SA SG11201507390SA SG11201507390SA SG11201507390SA SG 11201507390S A SG11201507390S A SG 11201507390SA SG 11201507390S A SG11201507390S A SG 11201507390SA SG 11201507390S A SG11201507390S A SG 11201507390SA SG 11201507390S A SG11201507390S A SG 11201507390SA
Authority
SG
Singapore
Prior art keywords
treatment
insulin resistance
resistance associated
physical inactivity
prolonged physical
Prior art date
Application number
SG11201507390SA
Other languages
English (en)
Inventor
Menghua Luo
Suzette Pereira
Neile Edens
Gerard Davis
Susan Gawel
Raj Chandran
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SG11201507390SA publication Critical patent/SG11201507390SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201507390SA 2013-03-14 2014-03-14 Treatment of insulin resistance associated with prolonged physical inactivity SG11201507390SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361783301P 2013-03-14 2013-03-14
US201361840990P 2013-06-28 2013-06-28
US201361866061P 2013-08-15 2013-08-15
PCT/US2014/027524 WO2014152606A2 (en) 2013-03-14 2014-03-14 Treatment of insulin resistance associated with prolonged physical inactivity

Publications (1)

Publication Number Publication Date
SG11201507390SA true SG11201507390SA (en) 2015-10-29

Family

ID=50549469

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507390SA SG11201507390SA (en) 2013-03-14 2014-03-14 Treatment of insulin resistance associated with prolonged physical inactivity

Country Status (11)

Country Link
US (1) US9713598B2 (zh)
EP (1) EP2968236A2 (zh)
JP (1) JP2016513701A (zh)
CN (1) CN105188695A (zh)
BR (1) BR112015022997A2 (zh)
CA (1) CA2904119C (zh)
HK (1) HK1220391A1 (zh)
MX (1) MX2015012821A (zh)
PH (1) PH12015502068A1 (zh)
SG (1) SG11201507390SA (zh)
WO (1) WO2014152606A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998870A1 (en) * 2015-09-16 2017-03-23 Metabolic Technologies, Inc. Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) for enhancing recovery from soft tissue trauma

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20060003959A1 (en) 2004-06-10 2006-01-05 Steven Burden Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
US7601370B2 (en) 2004-07-28 2009-10-13 Abbott Laboratories Method for controlling body weight in estrogen-insufficient women
JP2009501696A (ja) * 2005-04-27 2009-01-22 ティージーバイオテック インスリン抵抗性の治療
EP1774973A1 (en) * 2005-10-12 2007-04-18 Nutricia N.V. Leucine rich composition
JP5227182B2 (ja) 2005-12-19 2013-07-03 アボット・ラボラトリーズ １型および２型サイトカイン産生における不均衡を調節するためのベータ−ヒドロキシ−ベータ−メチルブチラートの使用
US20080171319A1 (en) 2006-02-06 2008-07-17 Mickey Urdea Osteoporosis associated markers and methods of use thereof
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
AU2010274125B2 (en) 2009-07-20 2015-11-05 Société des Produits Nestlé S.A. Methods of attenuating the loss of functional status
US20120231482A1 (en) 2009-11-13 2012-09-13 The Johns Hopkins University Method, kit or diagnostic for the detection of reagents which induce altered contractility
CA2784836C (en) 2009-12-18 2019-08-20 Metabolic Technologies, Inc. Improved method of administering .beta.-hydroxy-.beta.-methylbutyrate (hmb)
CN102770767A (zh) 2010-02-10 2012-11-07 诺瓦提斯公司 用于肌肉生长的方法和组合物
US20130338228A1 (en) * 2010-12-27 2013-12-19 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
KR20140054066A (ko) * 2011-07-15 2014-05-08 뉴서트 사이언시스, 인크. 대사 경로 조절을 위한 조성물 및 방법
CN104411305A (zh) * 2012-03-19 2015-03-11 雅培制药有限公司 用于改善葡萄糖耐受的β-羟基-β-甲基丁酸

Also Published As

Publication number Publication date
JP2016513701A (ja) 2016-05-16
BR112015022997A2 (pt) 2017-07-18
CA2904119A1 (en) 2014-09-25
CN105188695A (zh) 2015-12-23
US9713598B2 (en) 2017-07-25
EP2968236A2 (en) 2016-01-20
WO2014152606A2 (en) 2014-09-25
MX2015012821A (es) 2016-05-31
PH12015502068A1 (en) 2016-01-25
US20160022617A1 (en) 2016-01-28
WO2014152606A3 (en) 2015-02-05
CA2904119C (en) 2018-01-02
HK1220391A1 (zh) 2017-05-05

Similar Documents

Publication Publication Date Title
HK1218580A1 (zh) 胰島素時間-動作模型
HK1211944A1 (zh) 新穎的胰島素類似物及其用途
GB202005994D0 (en) Patient interface and aspects thereof
SG11201506979YA (en) Catheter assemblies with wipeable bloodstop and related methods
EP3398549C0 (en) BASKET CATHETER WITH DEFLECTABLE SPINDLE
ZA201506252B (en) Syringe
GB201307385D0 (en) Syringes
HK1217516A1 (zh) 與胰島素抗性進程相關的生物標誌物和其用途
IL269436A (en) Muscle in June
EP3006066A4 (en) INSTRUMENT FOR INJECTION, AND SYRINGE BULB
HK1224233A1 (zh) 注射器以及注射器組件
HK1223529A1 (zh) 針對患有糖尿病的人的低血糖治療
GB201318170D0 (en) Proteins with Diagnostic and Therapeutic Uses
GB201321078D0 (en) Syringe assemblies
HK1211455A1 (zh) 神經阻滯導管
EP3038675A4 (en) SYRINGE WITH INTEGRAL BULB
EP2978473A4 (en) AUTOMATIC RETRACTABLE SYRINGE
GB201408677D0 (en) Syringes
SG11201505250UA (en) Chair massager
EP3006067A4 (en) SYRINGE AND PRE-FILLED SYRINGE
HK1223834A1 (zh) 具有生物學活性的胰島素衍生物
HK1220391A1 (zh) 與長期體力活動不足有關的胰島素抗性的治療
GB201307872D0 (en) Medical use
TWM475183U (en) Insole with magnetic massage effect
GB201319004D0 (en) Medical use